The rise in the incidence of dapsone-resistant leprosy requires new therapeutic approaches. Based on the recommendations of the WHO and the experiences from many countries where leprosy is endemic, a standardized treatment regimen is presented. It is based on the combination of three chemotherapeutically active substances.